Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Bamlanivimab/etesevimab  COVID-19 treatment studies for Bamlaniv../e..  C19 studies: Bamlaniv../e..  Bamlaniv../e..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 67% Improvement Relative Risk Death/hospitalization 64% primary Hospitalization 61% c19early.org/l Bariola et al. Bamlanivimab/e.. for COVID-19 LATE Is late treatment with bamlanivimab/etesevimab beneficial for COVID-19? Retrospective 468 patients in the USA Lower death/hosp. (p=0.00029) and hospitalization (p=0.001) Bariola et al., medRxiv, doi:10.1101/2021.03.25.21254322 Favors bamlanivimab/e.. Favors control
Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection
Bariola et al., medRxiv, doi:10.1101/2021.03.25.21254322 (Preprint)
Bariola et al., Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with.., medRxiv, doi:10.1101/2021.03.25.21254322 (Preprint)
Mar 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 234 patients receiving bamlanivimab and 234 matched controls, showing lower hospitalization and mortality with treatment. Greater benefit was seen with administration within 4 days of their positive COVID-19 test.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, VanBlargan].
risk of death, 66.8% lower, RR 0.33, p = 0.05, treatment 4 of 234 (1.7%), control 12 of 234 (5.1%), NNT 29, odds ratio converted to relative risk.
risk of death/hospitalization, 64.3% lower, RR 0.36, p < 0.001, treatment 16 of 234 (6.8%), control 45 of 234 (19.2%), NNT 8.1, odds ratio converted to relative risk, primary outcome.
risk of hospitalization, 60.7% lower, RR 0.39, p = 0.001, treatment 15 of 234 (6.4%), control 39 of 234 (16.7%), NNT 9.8, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bariola et al., 30 Mar 2021, retrospective, USA, preprint, 22 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBamlaniv../e..All
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.03.25.21254322; this version posted March 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Impact of monoclonal antibody treatment on hospitalization and mortality among non- 2 hospitalized adults with SARS-CoV-2 infection 3 4 Authors: J. Ryan Bariola MD1, Erin K. McCreary PharmD1, Richard J. Wadas MD2, Kevin E. 5 Kip PhD3, Oscar C. Marroquin MD3, Tami Minnier MSN, RN4, Stephen Koscumb BS3, Kevin 6 Collins BS3, Mark Schmidhofer MD5, Judith A. Shovel BSN RN4, Mary Kay Wisniewski, MT 7 MA COM4, Colleen Sullivan MHA6, Donald M. Yealy MD2, David A Nace MD MPH7, David 8 T. Huang MD MPH2,8,9, Ghady Haidar MD1, Tina Khadem PharmD1, Kelsey Linstrum MS6,9, 9 Christopher W. Seymour MD MSc6,9, Stephanie K. Montgomery MS6,9, Derek C. Angus MD 10 MPH FRCP6,8,9, Graham M. Snyder MD SM1 11 1. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of 12 13 14 Medicine, Pittsburgh, PA, USA 2. Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 15 3. Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA 16 4. Wolff Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA 17 5. Division of Cardiology, Dept of Medicine, University of Pittsburgh School of Medicine, 18 Pittsburgh, PA, USA 19 6. UPMC Health System Office of Healthcare Innovation, Pittsburgh, PA, USA 20 7. Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh, 21 22 23 Pittsburgh, PA, USA 8. Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.03.25.21254322; this version posted March 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 24 9. Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, 25 Department of Critical Care Medicine, University of Pittsburgh School of Medicine, 26 Pittsburgh, PA, USA 27 28 Corresponding Author: 29 Graham M. Snyder, MD SM 30 Address: 3601 Fifth Avenue, Suite 150, Pittsburgh, PA 15213 31 Phone/Fax: 412-647-6718/412-692-2768 32 Email: snydergm3@upmc.edu 33 Keywords: COVID-19, SARS-CoV-2, monoclonal antibodies, bamlanivimab, etesevimab, 34 casirivimab, imdevimab 35 2 medRxiv preprint doi: https://doi.org/10.1101/2021.03.25.21254322; this version posted March 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 36 ABSTRACT 37 Background: Monoclonal antibody (mAb) treatment may prevent complications of COVID-19. 38 We sought to quantify the impact of bamlanivimab monotherapy on hospitalizations and 39 mortality, as well as Emergency..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit